ProovStation Raises 10.4 Million Euros to Deploy the First Network of AI-assisted Testing Stations for the Sale of Used Vehicles
26.1.2023 09:00:00 CET | Business Wire | Press Release
Four years after its creation, Proovstation, the European leader in automated vehicle testing solutions assisted by Artificial Intelligence, announces the closing of a new funding round of 10.4 million euro led by Supernova Invest, alongside Otium Capital, through its industrial venture fund, and Crédit Agricole Création. This fundraising will enable the startup to consolidate its pioneering role and to establish itself internationally as a key player in the used vehicles market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230126005107/en/
From left to right: Anton Komyza CFO & Cofounder, Cédric Bernard CEO & Cofounder, Gabriel Tissandier General Director & Cofounder (Photo: ProovStation)
ProovStation, a France-based company with 50 employees, is the industrial deeptech startup behind the first automobile scanner that fully automates the inspection and valuation process for used vehicles in 3 seconds.
A unique experience for car owners
ProovStation has transformed a previously manual, subjective and time-consuming process taking up to 30 minutes into one of industrial speed and quality capable of managing several hundred vehicles per day. The ProovStation stations, built in France, use a new generation AI based on the latest NVIDIA graphic cards and a cutting-edge optronic system which allow them to perform a 360° scan of the vehicle in just three seconds. More than 300 photos are taken and analysed by its algorithms before making a complete diagnosis. Covering all viewing angles, the station identifies all defects with millimetre precision and automatically generates an exhaustive and quantified inspection report listing the vehicle’s defects.
Through a partnership between ProovStation, Carrefour – Europe’s leading food retailer, Michelin – the world’s leading tyre manufacturer and the leader in mobility, and BCA Group – the European leader in used car sales, the startup is revolutionising the used vehicles sector by offering all car owners a unique, simple, reliable and instantaneous digital sales experience. The Proovstation automobile scanners, enhanced by the MICHELIN Quickscan® technology which automatically tests tire wear, are already available free-of-charge for self-service in the parking lots of several Carrefour hypermarkets in France. These allow car owners to obtain an instantaneous firm offer (non-binding unless specifically approved by them), guaranteed by BCA Group, for their vehicle at a fair price relative to the market based on the objective evaluation of its condition.
Develop the network of scanners and accelerate international growth
This €10m fundraising, led by Supernova Invest alongside Otium Capital, through its Industrial Venture fund, and Crédit Agricole Création, will enable ProovStation to densify its network of scanners throughout France, with around 30 deployments already planned in 2023. The company also aims to hasten its international expansion at used vehicle professionals to become a standard in the industry. The ProovStation network already has more than 130 stations under deployment in 13 countries on three continents at well-known groups such as SiXT, le Groupe BERNARD, le Groupe Starterre, le Groupe Charles André and BCA Group. The winner of the i-Nov 2020 award, ProovStation, alongside other national technology icons, is helping to boost the international prestige of the French mobility industry.
“We are proud of closing this funding round, which will allow us to give each driver an access to our service within less than 30 minutes of their homes”, says Cédric Bernard, CEO and co-founder of ProovStation. “Thanks to these funds, we will be able to invest in our technology to reinforce our international leadership. They will also give us the means to accelerate our expansion in the automotive industry to boost our already vigorous growth”.
David Hansen, Investment Director at Supernova Invest, says: “ProovStation is the perfect example of a forward-looking deeptech solution: a cutting-edge technology coupled with unique artificial intelligence capable of processing industrial-scale flows. We are convinced that the founders’ vision, together with ProovStation’s first-class team, will enable them to attain their growth targets, including internationally, where the market is extremely buoyant and awaiting a solution as advanced as that offered by ProovStation.”
Pierre Ménard, Principal Industrial Venture at Otium Capital, adds: “ProovStation is a project led by ambitious founders, built around a disruptive innovation in a deep market. The three key ingredients for success are there. We are happy to accompany them in this deployment phase and to help them revolutionize the used vehicle market.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005107/en/
Contact information
Press contacts
Ilinca Spita (EN)
(33)6-64-75-12-98
ilinca@edifice-communication.com
Stéphane Laurain
(33)6-98-58-38-35
stephane@edifice-communication.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press Release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press Release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press Release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press Release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press Release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
